Into cervical
cancer risk


Making sure that your patients are screened for cervical cancer is a critical component of their overall health. The new 2020 Quest Diagnostics Health Trends™ retrospective, longitudinal study confirms the value of co-testing in women ages 30 to 65.1

Comprehensive testing from Quest Diagnostics

For more than 50 years, we’ve been committed to providing diagnostic insights that can help you and your patients work together for better health. You can count on Quest for co-testing solutions that give you a more complete picture to help you make more informed decisions. We offer:

Cervical cancer screenings based on guidelines from many leading health societies
Aged-based Smart Codes provide cervical cancer screening based on ACOG guidelines and STI testing as appropriate
Liquid-based Pap tests to detect abnormal cells on the cervix
Aptima® HPV mRNA testing to detect presence and activity of infection
Enhanced reporting with CytoComplete for integrated, streamlined results for Pap and HPV
Biopsy confirmation of current and prior Pap results so a re-biopsy can be recommended when appropriate
Patient resources that drive engagement

Test ordering information

For more information on the following tests, or for a complete list of available tests, click below to visit our test directory.

Test code Test name
91384 Image-Guided Pap with Age-Based Screening Protocols
91385 Image-Guided Pap with Age-Based Screening with CT/NGa
91386 Image-Guided Pap with Age-Based Screening with CT/NG, Trichomonasb


a CT/NG: Chlamydia trachomatis/Neisseria gonorrhoeae
b CT/NG/Trich: Chlamydia trachomatis/Neisseria gonorrhoeae/Trichomonas vaginalis. Panel components can be ordered separately if not using Smart Codes. Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital (11363), Trichomonas vaginalis RNA, Qualitative, TMA, Pap Vial (90521)

Both imaged and non-imaged Pap tests are acceptable under the American College of Obstetricians and Gynecologists (ACOG) recommendations. Non-imaged Paps, as well as additional testing recommended by ACOG, are available at Quest Diagnostics, and may be ordered individually. Go to for our full test menu.

  1. Kaufman HW, Alagia DP, Chen Z, Onisko A, Austin RM. Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in co-testing for detection of cervical cancer and precancer in the United States. Am J Clin Pathol. Published online ahead of print. July 8, 2020. doi:10.1093/ajcp/aqaa074